Silvia Pelucchi

Silvia Pelucchi

Auto-generated profile, based on publicly available information

Silvia Pelucchi

Department of Pharmacological and Biomolecular Sciences, “Rodolfo Paoletti”, University of Milan, Milan, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
EMElena Marcello
Elena Marcello
CSClaudia Saraceno
Claudia Saraceno
SMStefano Musardo
Stefano Musardo
HVHugo Vara
Hugo Vara
AFAlerie Guzman de la Fuente
Alerie Guzman de la Fuente
MLMonica Di Luca
Monica Di Luca
A disintegrin and metalloproteinase 10 (ADAM10), a disintegrin and metalloproteinase that resides in the postsynaptic densities (PSDs) of excitatory synapses, has previously been shown to limit β-amyloid peptide (Aβ) formation in Alzheimer’s disease (AD). ADAM10 also plays a critical role in regulating functional membrane proteins at the synapse. Using human hippocampal homogenates, we found that ADAM10 removal from the plasma membrane was mediated by clathrin-dependent endocytosis. Additionally, we identified the clathrin adaptor AP2 as an interacting partner of a previously uncharacterized atypical binding motif in the ADAM10 C-terminal domain. This domain was required for ADAM10 endocytosis and modulation of its plasma membrane levels. We found that the ADAM10/AP2 association was increased in the hippocampi of AD patients compared with healthy controls. Long-term potentiation (LTP) in hippocampal neuronal cultures induced ADAM10 endocytosis through AP2 association and decreased surface ADAM10 levels and activity. Conversely, long-term depression (LTD) promoted ADAM10 synaptic membrane insertion and stimulated its activity. ADAM10 interaction with the synapse-associated protein-97 (SAP97) was necessary for LTD-induced ADAM10 trafficking and required for LTD maintenance and LTD-induced changes in spine morphogenesis. These data identify and characterize a mechanism controlling ADAM10 localization and activity at excitatory synapses that is relevant to AD pathogenesis.

18 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJennifer Stanic
Jennifer Stanic
MCMario Carta
Mario Carta
IEIvano Eberini
Ivano Eberini
SPSilvia Pelucchi
Silvia Pelucchi
EMElena Marcello
Elena Marcello
FGFabrizio Gardoni
Fabrizio Gardoni
NMDA receptor (NMDAR) composition and synaptic retention represent pivotal features in the physiology and pathology of excitatory synapses. Here, we identify Rabphilin 3A (Rph3A) as a new GluN2A subunit-binding partner. Rph3A is known as a synaptic vesicle-associated protein involved in the regulation of exo- and endocytosis processes at presynaptic sites. We find that Rph3A is enriched at dendritic spines. Protein–protein interaction assays reveals that Rph3A N-terminal domain interacts with GluN2A(1349–1389) as well as with PSD-95(PDZ3) domains, creating a ternary complex. Rph3A silencing in neurons reduces the surface localization of synaptic GluN2A and NMDAR currents. Moreover, perturbing GluN2A/Rph3A interaction with interfering peptides in organotypic slices orin vivoinduces a decrease of the amplitude of NMDAR-mediated currents and GluN2A density at dendritic spines. In conclusion, Rph3A interacts with GluN2A and PSD-95 forming a complex that regulates NMDARs stabilization at postsynaptic membranes.

1 May 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PMPatricia Regina Manzine
Patricia Regina Manzine
MEMiren Ettcheto
Miren Ettcheto
ACAmanda Cano
Amanda Cano
OFOriol Busquets Figueras
Oriol Busquets Figueras
EMElena Marcello
Elena Marcello
MARCIA COMINETTIMARCIA COMINETTI
MARCIA COMINETTI
Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates.

30 October 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
LALaura Alberio
Laura Alberio
ALAndrea Locarno
Andrea Locarno
ASAndrea Saponaro
Andrea Saponaro
EREdoardo Romano
Edoardo Romano
VBValerie Bercier
Valerie Bercier
AMAnna Moroni
Anna Moroni

28 November 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
PMPatricia Regina Manzine
Patricia Regina Manzine
SPSilvia Pelucchi
Silvia Pelucchi
MHMaria Aderuza Horst
Maria Aderuza Horst
FVFrancisco A.C. Vale
Francisco A.C. Vale
SPSofia C.I. Pavarini
Sofia C.I. Pavarini
MARCIA COMINETTIMARCIA COMINETTI
MARCIA COMINETTI
ADAM10 is the α-secretase that cleaves amyloid-β protein precursor in the non-amyloidogenic pathway in Alzheimer’s disease (AD) and is known to be regulated by different microRNAs (miRNAs), which are post-transcriptional regulators related to several

3 October 2017 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
EMElena Marcello
Elena Marcello
BBBarbara Borroni
Barbara Borroni
SPSilvia Pelucchi
Silvia Pelucchi
FGFabrizio Gardoni
Fabrizio Gardoni
MLMonica Di Luca
Monica Di Luca
Introduction: In the central nervous system a disintegrin and metalloproteinase 10 (ADAM10) controls several functions such as neurodevelopment, synaptic plasticity and dendritic spine morphology thanks to its activity towards a high number of substrates, including the synaptic cell adhesion molecules as the Amyloid Precursor Protein, N-cadherin, Notch and Ephrins. In particular, ADAM10 plays a key role in the modulation of the molecular mechanisms responsible for dendritic spine formation, maturation and stabilization and in the regulation of the molecular organization of the glutamatergic synapse. Consequently, an alteration of ADAM10 activity is strictly correlated to the onset of different types of synaptopathies, ranging from neurodevelopmental disorders, i.e. autism spectrum disorders, to neurodegenerative diseases, i.e. Alzheimer’s Disease. Areas covered: We describe the most recent discoveries in understanding of the role of ADAM10 activity at the glutamatergic excitatory synapse and its involvement in the onset of neurodevelopmental and neurodegenerative disorders. Expert opinion: A progress in the understanding of the molecular mechanisms driving ADAM10 activity at synapses and its alterations in brain disorders is the first step before designing a specific drug able to modulate ADAM10 activity.